The predictive accuracy of systemic immune-inflammation index and lymphocyte-to-monocyte ratio for extrapulmonary complications in pediatric Mycoplasma pneumoniae pneumonia: a retrospective cohort study
Han Song, Jingrong Fan, Hui Wang, Dan Li, Chunmei Zhu, Lei Yu · 2025
Read The predictive accuracy of systemic immune-inflammation index and lymphocyte-to-monocyte ratio for extrapulmonary complications in pediatric Mycoplasma pneumoniae pneumonia: a retrospective cohort study by Han Song, Jingrong Fan, Hui Wang, Dan Li, Chunmei Zhu, Lei Yu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12771173.txt.
Introduction
Song and co-authors test whether two blood ratios can warn that a child's pneumonia is spreading harm beyond the lungs. The infection, caused by the germ Mycoplasma pneumoniae, can trigger skin, gut, heart, blood, kidney, and joint problems. Their 2025 study reviews 160 children treated in Beijing in early 2025, of whom 48 had such complications.
Children with complications stayed longer and showed higher white cell counts and inflammation markers. One ratio, built from immune cell counts, ran higher in that group, while a lymphocyte-to-monocyte ratio ran lower. Both ratios plus a standard inflammation marker predicted complications on their own. The immune index alone scored best, and all three together scored better still. The authors propose the trio as a cheap early warning.
Catalog record
| CREATOR | Han Song, Jingrong Fan, Hui Wang, Dan Li, Chunmei Zhu, Lei Yu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The predictive accuracy of systemic immune-inflammation index and lymphocyte-to-monocyte ratio for extrapulmonary complications in pediatric Mycoplasma pneumoniae pneumonia: a retrospective cohort study Authors: Han Song, Jingrong Fan, Hui Wang, Dan Li, Chunmei Zhu, Lei Yu Published: 2025 ABSTRACT BackgroundThe prediction of extrapulmonary complications (EP complications) in pediatric Mycoplasma pneumoniae pneumonia (MPP) remains challenging, and the current biomarkers have limitations. This study aimed to investigate the role of the systemic immune-inflammation index (SIRI) and lymphocyte-to-monocyte ratio (LMR) in predicting EP complications in pediatric MPP cases.MethodsA total of 160 pediatric MPP cases who visited Capital Center for Children’s Health, Capital Medical University, between January 2025 and February 2025 were retrospectively analyzed. The patients were recruited using a consecutive sampling method, and the cases were divided into two categories depending on whether EP complications were present, forming the MPP group (n=112) and the MPP + EP group (n=48). EP complications were defined using a composite reference standard, which included skin involvement, gastrointestinal symptoms, circulatory complications, hematologic abnormalities, urinary manifestations, and arthritis. Baseline characteristics of both groups were compared to assess differences in demographic and clinical factors. To explore potential factors associated with EP complications, both univariate and multivariate logistic regression models were utilized. The ability of SIRI, LMR, and C-reactive protein (CRP) to indicate diagnostic relevance was assessed through receiver operating characteristic (ROC) curve analysis, with the area under the curve (AUC) computed for performance evaluation.ResultsCases in the MPP + EP group showed longer hospitalization, higher white blood cell (WBC) counts, and elevated CRP levels compared to the MPP group (P<0.001). SIRI was significantly higher (P<0.001), while LMR was lower (P=0.001) in cases with EP complications. Multivariate logistic regression identified SIRI [odds ratio (OR) =1.007, P<0.001], CRP (OR =1.199, P=0.03), and LMR (OR =0.143, P<0.001) as independent predictors. ROC analysis showed that SIRI had the highest predictive accuracy (AUC =0.824, sensitivity =75.0%, specificity =89.3%), followed by CRP (AUC =0.717, sensitivity =77.1%, specificity =62.5%) and LMR (AUC =0.673, sensitivity =58.9%, specificity =70.8%). The combination of SIRI, CRP, and LMR improved performance (AUC =0.858, sensitivity =75.0%, specificity =92.9%). The cross-tabulation of test results against the reference standard showed that for CRP, 42 MPP cases and 37 MPP + EP cases were positive, and 70 MPP cases and 11 MPP + EP cases were negative. For SIRI, 12 MPP cases and 36 MPP + EP cases were positive, and 100 MPP cases and 12 MPP + EP cases were negative. For LMR, 46 MPP cases and 34 MPP + EP cases were positive, and 66 MPP cases and 14 MPP + EP cases were negative.ConclusionsSIRI and LMR are valuable inflammatory biomarkers for predicting EP complications in pediatric MPP cases. Higher SIRI and CRP levels were linked to an increased risk of extrapulmonary involvement, while lower LMR appeared to be protective. The combination of these markers enhances predictive accuracy, supporting their potential clinical utility in risk stratification and early intervention strategies. Highlight box Key findings • Systemic immune-inflammation index (SIRI) and lymphocyte-to-monocyte ratio (LMR) are valuable inflammatory biomarkers for predicting extrapulmonary complications (EP complications) in pediatric Mycoplasma pneumoniae pneumonia (MPP) cases. What is known and what is new? • SIRI and LMR have been investigated in several conditions, including sepsis, malignancies, and autoimmune diseases, and have demonstrated promising prognostic value in predicting disease severity and systemic inflammatory burden. • The present study aimed to investigate the predictive value of SIRI and LMR in the early onset of EP complications among children diagnosed with MPP. What are the implications, and what should change now? • Higher SIRI and C-reactive protein levels were linked to an increased risk of extrapulmonary involvement, while lower LMR appeared to be protective. The combination of these markers enhances predictive accuracy, supporting their potential clinical utility in risk stratification and early intervention strategies. Introduction Mycoplasma pneumoniae pneumonia (MPP) is one of the leading causes of community-acquired pneumonia in children, accounting for a significant proportion of pediatric respiratory infections globally (1,2). Although MPP is often self-limiting and responsive to macrolide treatment, an increasing number of cases present with severe disease progression and extrapulmonary complications (EP complications), posing challenges in clinical management (3,4). These complications can involve multiple organ systems, including the skin, digestive, circulatory, hematologic, urinary and central nervous system, leading to significant morbidity and prolonged hospitalization in affected children (4,5). The exact pathophysiology of extrapulmonary involvement in MPP remains unclear, but it is believed to be primarily mediated by immune dysregulation rather than direct Mycoplasma pneumoniae invasion (6-8). Several mechanisms have been proposed, including molecular mimicry, cytokine storm, immune complex deposition, and autoimmune responses, all of which can contribute to systemic inflammatory damage and organ dysfunction (6-8). Given these immunopathological features, inflammatory biomarkers may play a crucial role in identifying cases at risk for severe or extrapulmonary involvement, thereby facilitating early intervention and improved clinical outcomes. Inflammatory indicators, including white blood cell (WBC) count, C-reactive protein (CRP), and other related biomarkers, have traditionally served as reference parameters to evaluate the extent of disease progression and severity in pediatric MPP cases (9,10). However, their predictive value for extrapulmonary involvement remains limited and inconsistent, as they do not fully capture the complex immune-inflammatory interactions associated with MPP pathogenesis. Therefore, novel biomarkers capable of reflecting systemic immune and inflammatory responses more comprehensively are urgently needed for early risk stratification and improved prognostic assessment. In recent years, two emerging immune-inflammatory indices—the systemic immune-inflammation index (SIRI) and the lymphocyte-to-monocyte ratio (LMR)—have gained attention as potential markers of systemic inflammation and immune response dysregulation in various infectious and inflammatory diseases (11,12). SIRI, determined by the formula below (neutrophil count × monocyte count)/lymphocyte count, functions as a marker of systemic immune response and inflammatory activity, representing the interplay among neutrophil-associated inflammatory processes, monocyte-influenced immune modulation, and lymphocyte-driven regulatory mechanisms (13,14). In contrast, LMR, defined as lymphocyte count/monocyte count, represents the host immune status, with lower LMR values often associated with immune suppression and uncontrolled inflammation (15,16). These indices have been investigated in several conditions, including sepsis, malignancies, and autoimmune diseases, and have demonstrated promising prognostic value in predicting disease severity and systemic inflammatory burden. EP complications in pediatric MPP remain challenging to predict, and current biomarkers have limitations. Biomarkers such as CRP, procalcitonin (PCT), and cytokines [e.g., interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α)] have poor specificity, limited predictive accuracy, and high costs. CRP, though commonly used, is nonspecific, while PCT lacks sufficient sensitivity for predicting extrapulmonary involvement. Given the immunopathology of MPP, which involves complex immune dysregulation, we hypothesize that the SIRI and LMR may offer superior predictive value. SIRI integrates inflammatory markers like neutrophils, monocytes, and lymphocytes, providing a broader view of systemic inflammation, while LMR, reflecting the balance between lymphocytes and monocytes, may help identify patients at risk for EP complications. These biomarkers could improve early detection and risk stratification, addressing the limitations of existing markers and enhancing clinical outcomes. However, their role in predicting EP complications in pediatric MPP remains largely unexplored. Therefore, we performed this study to investigate the predictive value of SIRI and LMR in the early onset of EP complications among children diagnosed with MPP. We present this article in accordance with the TRIPOD reporting checklist (available at https://tp.amegroups.com/article/view/10.21037/tp-2025-488/rc). Methods Participants enrollment and study design